This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brossier, F.
Right arrow Articles by Mock, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brossier, F.
Right arrow Articles by Mock, M.

 Previous Article  |  Next Article 

Infection and Immunity, February 1999, p. 964-967, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Functional Analysis of the Carboxy-Terminal Domain of Bacillus anthracis Protective Antigen

Fabien Brossier, Jean-Claude Sirard, Chantal Guidi-Rontani, Edith Duflot, and Michele Mock*

Unité Toxines et Pathogénie Bactériennes, Institut Pasteur, 75724 Paris Cedex 15, France

Received 3 September 1998/Returned for modification 10 November 1998/Accepted 30 November 1998


    ABSTRACT
Top
Abstract
Text
References

Protective antigen (PA) is the common receptor-binding component of the two anthrax toxins. We investigated the involvement of the PA carboxy-terminal domain in the interaction of the protein with cells. A deletion resulting in removal of the entire carboxy-terminal domain of PA (PA608) or part of an exposed loop of 19 amino acids (703 to 722) present within this domain was introduced into the pag gene. PA608 did not induce the lethal-factor (LF)-mediated cytotoxic effect on macrophages because it did not bind to the receptor. In contrast, PA711- and PA705-harboring lethal toxins (9- and 16-amino-acid deletions in the loop, starting after positions 711 and 705, respectively) were 10 times less cytotoxic than wild-type PA. After cleavage by trypsin, the mutant PA proteins formed heptamers and bound LF. The capacity of PA711 and PA705 to interact with cells was 1/10 that of wild-type PA. In conclusion, truncation of the carboxy-terminal domain or deletions in the exposed loop resulted in PA that was less cytotoxic or nontoxic because the mutated proteins did not efficiently bind to the receptor.


    TEXT
Top
Abstract
Text
References

Bacillus anthracis, a spore-forming bacterium, is the causative agent of anthrax. The two exotoxins are main virulence factors of the microorganism. These toxins are composed of three proteins: the protective antigen (PA, 83 kDa), the lethal factor (LF, 85 kDa), and the edema factor (EF, 89 kDa) (7, 15). Intravenous injection of the lethal toxin (PA plus LF) causes sudden death in animals (1). The edema toxin (PA plus EF) causes edema at the inoculation site (29). The components PA, LF, and EF are encoded by the pag, lef, and cya genes, respectively, and these genes are carried by virulence plasmid pXO1 (185 kbp) (3, 17, 20, 32). A mode of action has been proposed for anthrax toxins (13). PA binds to a ubiquitous proteinaceous cell receptor which has yet to be identified (6). It is then cleaved by a furin-like protease into PA63 and PA20 (a 20-kDa amino-terminal fragment) (11, 26). This processing facilitates the heptamerization of PA63 (19) and the subsequent binding of EF or LF. These toxic complexes are internalized by receptor-mediated endocytosis. The pH within the acidic vesicles decreases during intracellular trafficking, resulting in the insertion of PA into the membrane and the formation of a channel (2, 12, 18). EF and LF are further translocated into the cytoplasm to exert their catalytic effects. EF is a calmodulin-dependent adenylate cyclase (14). LF is a zinc metalloprotease which cleaves mitogen-activated protein kinase kinases 1 and 2 (5, 10, 31). The lethal toxin induces the lysis of macrophage cell lines such as RAW264.7 (8). PA is therefore a key protein, promoting both the binding of the toxins and the translocation of their enzymatic moieties (27, 33). Previous studies have suggested that the carboxy-terminal extremity of PA is involved in the recognition of the cell receptor (16, 28). The three-dimensional structure of the monomeric PA has been solved at 2.1 Å resolution (21) and consists of four folding domains. Domain 4 of PA encompasses the last 139 carboxy-terminal amino acids (596 to 735). We analyzed the function of domain 4 in toxicity by constructing various deletions in the pag gene, based on the structural organization of the molecule. The cytotoxicity of the resulting protein products in the presence of LF and their interaction with the receptor were tested.

Construction of carboxy-terminal domain mutant PA. Domain 4 of PA contains an exposed loop of 19 amino acids which begins at position 703. Mutations affecting the whole of domain 4 of PA or the exposed loop were produced (Fig. 1). We thereby created stop codons after the sequences encoding arginine 592 (PA592) or aspartate 608 (PA608), removing the whole of domain 4 (PA592) or retaining the first 16 amino acids of this domain (PA608). Two short, in-frame deletions resulting in the removal of 9 (PA711) or 16 (PA705) amino acids from the loop were created after the nucleotides encoding residues 711 and 705, respectively. Mutants PA proteins were obtained by site-directed mutagenesis with a PCR. Plasmid pACP41 was used as the template for the PCR (23). The divergent sequences of the primers used were 5'-AAGAAAATTTTAATCTTTTCTAAAAAAGGC-3' and 5'-GTTTTCTTTAGTAACAGCATATACATTTAC-3' for PA705, 5'-ACTAGGATTAATAATAGTGTTTTCTTTAG-3' and 5'-ATCAAGAAAATTTTAATCTTTTCTAAAAAAGGC-3' for PA711, and 5'-CTCACTAATCCGCCCCAACTGCTATG-3' and 5'-GGCTATGAGATAGGATAAGGTAATTCT-3' for PA608. For the construction of PA592, a stop codon was introduced by using a site-directed mutagenesis kit (Stratagene, La Jolla, Calif.). The mutated pag genes, cloned into shuttle plasmid pAT28 (30), were transferred by heterogramic mating as previously described (22) into PA-deficient B. anthracis RP31 (23), and the production of PA-related proteins was tested. The three mutated proteins, PA608, PA705, and PA711, were purified by fast protein liquid chromatography as previously described (23) from the supernatants of B. anthracis transconjugants grown in R medium (24) containing tryptone (5 g/liter). The molecular masses of the corresponding proteins were as expected (approximately 83 kDa for PA711 and PA705 and 70 kDa for PA608) (Fig. 2). In contrast, PA592 was not found in the supernatants of B. anthracis, suggesting that the amino acids between asparagine 592 and aspartate 608 are required for stability of the molecule.


View larger version (47K):
[in this window]
[in a new window]
 
FIG. 1.   Schematic representation of the mutagenesis of domain 4 of PA. The three-dimensional structure of the carboxy-terminal domain of PA (amino acids 592 to 735), according to Petosa et al. (21), is shown. We truncated the PA molecule by introducing a stop codon after the codon encoding arginine 592 or aspartate 608. Two in-frame deletions resulting in the removal of 9 and 16 amino acids (residues 711 to 721 and 705 to 722, respectively) were also created in the exposed loop of 19 amino acids (residues 703 to 722). Point mutations are indicated by dashed arrows; deletions are indicated by plain arrows.


View larger version (57K):
[in this window]
[in a new window]
 
FIG. 2.   Trypsin treatment of mutant PA. Wild-type and mutant PA proteins were purified from B. anthracis supernatants and studied in native form (-) or after (+) cleavage by trypsin. Samples (2 µg) were subjected to electrophoresis in a sodium dodecyl sulfate-12% polyacrylamide gel and stained with Coomassie blue. The values on the left are molecular masses in kilodaltons.

Cytotoxicity of mutant PA in the presence of LF. We tested the ability of PA mutant proteins to induce LF-mediated lysis of murine macrophage cell line RAW264.7 (Fig. 3). A 20-ng/ml concentration of wild-type PA was required for lysis of half of the macrophages (50% effective concentration [EC50]). PA608 was completely inactive against macrophages (EC50, >2 × 104 ng/ml). PA711 and PA705 were mildly toxic, with EC50s of 2 × 102 and 6 × 102 ng/ml, respectively (EC50 of PA, 20 ng/ml). To determine which step of the intoxication process was affected, we analyzed the interaction of the mutant PA with LF and with the cell receptor.


View larger version (21K):
[in this window]
[in a new window]
 
FIG. 3.   Cytotoxicity assay for mutant PA. Wild-type or mutated PA protein (from 1 × 2 × 104 to 2 × 104 ng/ml) was serially diluted into a 96-well plate containing RAW264.7 cells in the presence of a constant concentration of LF (2 × 104 ng/ml). The cells were incubated for 3 h, and their viability was assessed by using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (9). The experiment was carried out at least three times for each mutant PA protein.

Interaction of mutant PA with LF. The interaction between PA and LF requires the proteolytic processing of PA by the furin-like protease. In vitro, trypsin mimics this action, cleaving PA into PA20 and PA63. Treatment of PA705, PA711, and PA608 with trypsin (600:1) for 30 min at 30°C released PA20 and a PA63 mutant polypeptide of the expected size (Fig. 2). Thus, the trypsin-sensitive site was exposed in the mutant molecules. Moreover, PA705 and PA711 formed heptamers after processing, as previously observed for wild-type PA (19) (data not shown). An assay was developed to detect the binding of LF to the mutant PA molecules. Purified LF protein (1 µg per well) was subjected to electrophoresis in a nondenaturing polyacrylamide gel and transferred to a nitrocellulose membrane (Hybond-C; Amersham, Buckinghamshire, England). Wild-type or mutated PA proteins (2 µg/ml), freshly treated with trypsin, were incubated with the LF blots for 16 h at 4°C. The PA63-LF complex was detected by Western blotting using rabbit anti-PA serum, followed by the addition of goat anti-immunoglobulin G coupled to peroxidase (ECL kit; Amersham). Only the trypsin-treated forms of the PA proteins recognized LF on the membrane (Fig. 4). A double signal was routinely observed which corresponded to the two isoforms of LF. The three mutant proteins interacted with LF in a manner similar to that of wild-type PA. Thus, (i) the conformation of the LF-binding region of PA was not significantly changed and (ii) domain 4 of PA was not required for the binding of LF, consistent with previous reports (16, 28).


View larger version (30K):
[in this window]
[in a new window]
 
FIG. 4.   Interaction of mutant PA proteins with LF. Purified LF protein was subjected to electrophoresis in a 10% nondenaturing polyacrylamide gel and transferred to a nitrocellulose membrane under nondenaturing conditions. Wild-type or mutated PA proteins (2 µg), untreated (-) or treated (+) with trypsin, were added. The filter was incubated for 16 h at 4°C, and the LF-PA63 complex was detected with anti-PA serum.

Binding of mutant PA to cells. The binding of wild-type and mutant PA proteins to cells was tested on CHO-K1 cells, each of which has approximately 10,000 PA receptor molecules on its surface (6). An enzyme-linked immunosorbent assay was used to determine protein binding. The CHO-K1 cell line was seeded into 24-well plates (Costar) containing glass slides at a density of approximately 105 cells per well. The cells were incubated for 16 h at 37°C in a 5% CO2-95% air atmosphere, cooled for 15 min at 4°C, washed with cold phosphate-buffered saline (PBS), and incubated for 3 h at 4°C in RPMI 1640 with wild-type or mutant PA protein. Unbound proteins were removed by washing the cells with cold PBS. Cells were then fixed and then incubated with anti-PA serum (1/4,000) for 45 min at 37°C in PBS-skim milk powder (2%). After washing, goat anti-immunoglobulin G coupled to beta -galactosidase (1/10,000) was added and incubated with cells in PBS-skim milk powder (2%) for 45 min at 37°C. The glass slides were washed with PBS and incubated for 30 min at 37°C with methylumbelliferyl-beta -galactoside (MUG). The enzymatic reaction was stopped by addition of 100 mM glycine (pH 10.4). The hydrolysis of MUG by the beta -galactosidase resulted in the formation of a fluorescent component. The level of fluorescence associated with cells was assessed on a fluoroscan fluorimeter (Titertek-Fluoroskan, Labsystem).

The threshold for detection of wild-type PA was about 10 ng/ml, and the receptors were saturated at a concentration of 5 µg/ml (Fig. 5). The truncated protein, PA608, did not bind to cells, even at high concentrations (104 ng/ml), and the level of binding of PA711 and PA705 to cells was significantly lower (1/10) than that of the wild-type protein. Therefore, the low cytotoxicity of domain 4 mutant PA is due to a defect in the receptor interaction of these molecules. The 19-amino-acid loop of PA is structurally similar to the 15-amino-acid (from residue 516 to residue 530) exposed loop in the binding domain of the diphtheria toxin (4). Replacement of Lys 516 and Phe 530 with Ala results in mutant diphtheria toxins that are 22 and 10 times less cytotoxic than the wild-type protein, respectively, because the molecules do not efficiently bind to the receptor (25). The exposed loops of PA and the diphtheria toxin may have similar functions. They may be involved in stabilization of the toxin-receptor complex or may participate in receptor recognition.


View larger version (20K):
[in this window]
[in a new window]
 
FIG. 5.   Assay of binding of wild-type or mutant PA proteins to CHO-K1 cells. Various concentrations of wild-type or mutant PA proteins (from 10 to 1 × 104 ng/ml) were incubated with CHO-K1 cells for 3 h at 4°C. The binding of PA proteins to cells was detected with anti-PA serum and a secondary antibody coupled to beta -galactosidase. MUG was added as the substrate for beta -galactosidase, and fluorescence was quantified with a fluorimeter. The experiment was carried out at least three times for each mutant PA protein.


    ACKNOWLEDGMENTS

We are grateful to Carlo Petosa for helpful discussions on the design of mutant PA proteins. We also thank Evelyne Tosi-Couture for the observations by electron microscopy and Guy Patra for helpful discussions on the purification of the mutant PA proteins.

This work was supported by DRET (94-118). F.B. was supported by the Ministère de l'Enseignement Supérieur et de la Recherche.


    FOOTNOTES

* Corresponding author. Mailing address: Unité Toxines et Pathogénie Bactériennes (URA 1858, CNRS), Institut Pasteur, 28, rue du Dr. Roux, 75724 Paris Cedex 15, France. Phone: (33) 1.45.68.83.12. Fax: (33) 1.45.68.89.54. E-mail: mmock{at}pasteur.fr.

Editor:   J. T. Barbieri


    REFERENCES
Top
Abstract
Text
References

1. Beall, F. A., M. J. Taylor, and C. B. Thorne. 1962. Rapid lethal effects in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J. Bacteriol. 83:1274-1280[Abstract/Free Full Text].
2. Blaustein, R. O., T. M. Koehler, R. J. Collier, and A. Finkelstein. 1989. Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers. Proc. Natl. Acad. Sci. USA 86:2209-2213[Abstract/Free Full Text].
3. Bragg, T. S., and D. L. Robertson. 1986. Nucleotide sequence and analysis of the lethal factor gene (lef) from Bacillus anthracis. Gene 81:45-54.
4. Choe, S., M. J. Bennett, G. Fujii, P. M. G. Curmi, K. A. Kantardjieff, R. J. Collier, and D. Eisenberg. 1992. The crystal structure of diphtheria toxin. Nature 357:216-222[Medline].
5. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vandewoude. 1998. Proteolytic inactivation of map-kinase-kinase by anthrax lethal factor. Science 280:734-737[Abstract/Free Full Text].
6. Escuyer, V., and R. J. Collier. 1991. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect. Immun. 59:3381-3386[Abstract/Free Full Text].
7. Fish, D. C., B. G. Mahlandt, J. P. Dobbs, and R. E. Lincoln. 1968. Purification and properties of in vitro-produced anthrax toxin components. J. Bacteriol. 95:907-918[Abstract/Free Full Text].
8. Friedlander, A. M. 1986. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261:7123-7126[Abstract/Free Full Text].
9. Hansen, M. B., S. E. Nielsen, and K. Berg. 1989. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119:203-210[Medline].
10. Klimpel, K. R., N. Arora, and S. H. Leppla. 1994. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Microbiol. 13:1093-1100[Medline].
11. Klimpel, K. R., S. S. Molloy, G. Thomas, and S. H. Leppla. 1992. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. USA 89:10277-10281[Abstract/Free Full Text].
12. Koehler, T. M., and R. J. Collier. 1991. Anthrax toxin protective antigen: low pH-induced hydrophobicity and channel formation in liposomes. Mol. Microbiol. 5:1501-1506[Medline].
13. Leppla, S. H. 1991. The anthrax toxin complex, p. 277-302. In J. E. Alouf, and J. H. Freer (ed.), Sourcebook of bacterial protein toxins, vol. 14. Academic Press, San Diego, Calif.
14. Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells. Proc. Natl. Acad. Sci. USA 79:3162-3166[Abstract/Free Full Text].
15. Leppla, S. H. 1988. Production and purification of anthrax toxin. Methods Enzymol. 165:103-116[Medline].
16. Little, S. F., J. M. Novak, J. R. Lowe, S. H. Leppla, Y. Singh, K. R. Klimpel, B. C. Lidgerding, and A. M. Friedlander. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology (Reading) 142:707-715[Abstract/Free Full Text].
17. Mikesell, P., B. E. Ivins, J. D. Ristroph, and T. M. Dreier. 1983. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect. Immun. 39:371-376[Abstract/Free Full Text].
18. Milne, J. C., and R. J. Collier. 1993. pH-dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen. Mol. Microbiol. 10:647-653[Medline].
19. Milne, J. C., D. Furlong, P. C. Hanna, J. S. Wall, and R. J. Collier. 1994. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:20607-20612[Abstract/Free Full Text].
20. Mock, M., E. Labruyère, P. Glaser, A. Danchin, and A. Ullmann. 1988. Cloning and expression of the calmodulin-sensitive Bacillus anthracis adenylate cyclase in Escherichia coli. Gene 64:277-284[Medline].
21. Petosa, C., R. J. Collier, K. R. Klimple, S. H. Leppla, and R. Lidington. 1997. Crystal structure of the anthrax toxin protective antigen. Nature 385:933-938.
22. Pezard, C., P. Berche, and M. Mock. 1991. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 59:3472-3477[Abstract/Free Full Text].
23. Pezard, C., E. Duflot, and M. Mock. 1993. Construction of Bacillus anthracis mutant strains producing a single toxin component. J. Gen. Microbiol. 139:2459-2463[Abstract/Free Full Text].
24. Ristroph, J. D., and B. E. Ivins. 1983. Elaboration of Bacillus anthracis antigens in a new, defined culture medium. Infect. Immun. 39:483-486[Abstract/Free Full Text].
25. Shen, W. H., S. Y. Choe, D. Eisenberg, and R. J. Collier. 1994. Participation of lysine 516 and phenylalanine 530 of diphtheria toxin in receptor recognition. J. Biol. Chem. 269:29077-29084[Abstract/Free Full Text].
26. Singh, Y., V. K. Chaudhary, and S. H. Leppla. 1989. A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin in vivo. J. Biol. Chem. 264:19103-19107[Abstract/Free Full Text].
27. Singh, Y., K. R. Klimpel, N. Arora, M. Sharma, and S. H. Leppla. 1994. The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor. J. Biol. Chem. 269:29039-29046[Abstract/Free Full Text].
28. Singh, Y., K. R. Klimpel, C. P. Quinn, V. K. Chaudhary, and S. H. Leppla. 1991. The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. J. Biol. Chem. 266:15493-15497[Abstract/Free Full Text].
29. Stanley, J. L., and H. Smith. 1961. Purification of factor I and recognition of a third factor of anthrax toxin. J. Gen. Microbiol. 26:49-66[Abstract/Free Full Text].
30. Trieu-Cuot, P., C. Carlier, C. Poyart-Salmeron, and P. Courvalin. 1990. A pair of mobilisable shuttle vectors conferring resistance to spectinomycin for molecular cloning in Escherichia coli and Gram positive bacteria. Nucleic Acids Res. 18:4296[Free Full Text].
31. Vitale, G., R. Pellizzari, C. Recchi, G. Napolitani, M. Mock, and C. Montecucco. 1998. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248:706-711[Medline].
32. Vodkin, M. H., and S. H. Leppla. 1983. Cloning of the protective antigen gene of Bacillus anthracis. Cell 34:693-697[Medline].
33. Wang, W.-M., R. Wattiez, F. Brossier, M. Mock, P. Falmagne, J.-M. Ruysschaert, and V. Cabiaux. 1998. Use of a photoactivatable lipid to probe the topology of PA63 of Bacillus anthracis in lipid membranes. Eur. J. Biochem. 256:179-183[Medline].


Infection and Immunity, February 1999, p. 964-967, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Cao, S., Guo, A., Liu, Z., Tan, Y., Wu, G., Zhang, C., Zhao, Y., Chen, H. (2009). Investigation of New Dominant-Negative Inhibitors of Anthrax Protective Antigen Mutants for Use in Therapy and Vaccination. Infect. Immun. 77: 4679-4687 [Abstract] [Full Text]  
  • Chen, K.-H., Liu, S., Bankston, L. A., Liddington, R. C., Leppla, S. H. (2007). Selection of Anthrax Toxin Protective Antigen Variants That Discriminate between the Cellular Receptors TEM8 and CMG2 and Achieve Targeting of Tumor Cells. J. Biol. Chem. 282: 9834-9845 [Abstract] [Full Text]  
  • Zomber, G., Reuveny, S., Garti, N., Shafferman, A., Elhanany, E. (2005). Effects of Spontaneous Deamidation on the Cytotoxic Activity of the Bacillus anthracis Protective Antigen. J. Biol. Chem. 280: 39897-39906 [Abstract] [Full Text]  
  • Brossier, F., Levy, M., Landier, A., Lafaye, P., Mock, M. (2004). Functional Analysis of Bacillus anthracis Protective Antigen by Using Neutralizing Monoclonal Antibodies. Infect. Immun. 72: 6313-6317 [Abstract] [Full Text]  
  • Lacy, D. B., Wigelsworth, D. J., Melnyk, R. A., Harrison, S. C., Collier, R. J. (2004). Structure of heptameric protective antigen bound to an anthrax toxin receptor: A role for receptor in pH-dependent pore formation. Proc. Natl. Acad. Sci. USA 101: 13147-13151 [Abstract] [Full Text]  
  • Barth, H., Aktories, K., Popoff, M. R., Stiles, B. G. (2004). Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins. Microbiol. Mol. Biol. Rev. 68: 373-402 [Abstract] [Full Text]  
  • Mourez, M., Yan, M., Lacy, D. B., Dillon, L., Bentsen, L., Marpoe, A., Maurin, C., Hotze, E., Wigelsworth, D., Pimental, R.-A., Ballard, J. D., Collier, R. J., Tweten, R. K. (2003). Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis. Proc. Natl. Acad. Sci. USA 100: 13803-13808 [Abstract] [Full Text]  
  • Rosovitz, M. J., Schuck, P., Varughese, M., Chopra, A. P., Mehra, V., Singh, Y., McGinnis, L. M., Leppla, S. H. (2003). Alanine-scanning Mutations in Domain 4 of Anthrax Toxin Protective Antigen Reveal Residues Important for Binding to the Cellular Receptor and to a Neutralizing Monoclonal Antibody. J. Biol. Chem. 278: 30936-30944 [Abstract] [Full Text]  
  • Flick-Smith, H. C., Walker, N. J., Gibson, P., Bullifent, H., Hayward, S., Miller, J., Titball, R. W., Williamson, E. D. (2002). A Recombinant Carboxy-Terminal Domain of the Protective Antigen of Bacillus anthracis Protects Mice against Anthrax Infection. Infect. Immun. 70: 1653-1656 [Abstract] [Full Text]  
  • Mogridge, J., Mourez, M., Collier, R. J. (2001). Involvement of Domain 3 in Oligomerization by the Protective Antigen Moiety of Anthrax Toxin. J. Bacteriol. 183: 2111-2116 [Abstract] [Full Text]  
  • Brossier, F., Weber-Levy, M., Mock, M., Sirard, J.-C. (2000). Role of Toxin Functional Domains in Anthrax Pathogenesis. Infect. Immun. 68: 1781-1786 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brossier, F.
Right arrow Articles by Mock, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brossier, F.
Right arrow Articles by Mock, M.